Bumetanide Oral Liquid Formulation for the Treatment of Children and Adolescents with Autism Spectrum Disorder: Design of Two Phase III Studies (SIGN Trials)

There are currently no approved pharmacological treatments to improve social reciprocity and limit repetitive and rigid behaviors in autism spectrum disorder (ASD). We describe the design of two Phase III studies evaluating the efficacy/safety of bumetanide oral liquid formulation in ASD. These are...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Autism Dev Disord
Main Authors: Crutel, Véronique, Lambert, Estelle, Penelaud, Pierre-François, Albarrán Severo, Cristina, Fuentes, Joaquin, Rosier, Antoine, Hervás, Amaia, Marret, Stéphane, Oliveira, Guiomar, Parellada, Mara, Kyaga, Simon, Gouttefangeas, Sylvie, Bertrand, Marianne, Ravel, Denis, Falissard, Bruno
Formato: Artigo
Idioma:Inglês
Publicado: Springer US 2020
Assuntos:
Original Paper
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC8254707/
https://ncbi.nlm.nih.gov/pubmed/33151500
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10803-020-04709-8
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares